WILLIAM G. BAKER, M.D.; NILS U. BANG, M.D.; RALPH L. NACHMAN, M.D.; FARRO RAAFAT, M.D.; HERBERT I. HOROWITZ, M.D.
Hemorrhage is a frequent complication of acute leukemia. A recent review of acute leukemia presented evidence of bleeding in 66% of 322 cases and showed that it was the principal cause of death in 44% (1). The pathogenesis of hemorrhage in most cases of acute leukemia is quite obvious: leukemic replacement of normal bone marrow results in severe thrombocytopenia (2, 3). Occasionally, the cause is more obscure, being variously ascribed to qualitative platelet deficiencies (4), vascular endothelial damage from anoxia or lysins (5), leukemic infiltration of vessel walls (6), or circulating anticoagulants (7, 8). Recent studies report that in certain
WILLIAM G. BAKER, NILS U. BANG, RALPH L. NACHMAN, FARRO RAAFAT, HERBERT I. HOROWITZ. Hypofibrinogenemic Hemorrhage in Acute Myelogenous Leukemia Treated with Heparin: With Autopsy Findings of Widespread Intravascular Clotting. Ann Intern Med. 1964;61:116–123. doi: 10.7326/0003-4819-61-1-116
Download citation file:
Published: Ann Intern Med. 1964;61(1):116-123.
Coagulopathies, Hematology/Oncology, Leukemia/Lymphoma.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use